tetano
Editor, Senior Moderator
Antivir Ther. 2017 Nov 29. doi: 10.3851/IMP3210. [Epub ahead of print]
[h=1]Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.[/h] Favi? LM[SUP]1[/SUP], Murk JL[SUP]2[/SUP], Meijer A[SUP]3[/SUP], Nijstad AL[SUP]1[/SUP], van Maarseveen EM[SUP]1[/SUP], Sikma MA[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous hemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.
PMID: 29185991 DOI: 10.3851/IMP3210
[h=1]Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.[/h] Favi? LM[SUP]1[/SUP], Murk JL[SUP]2[/SUP], Meijer A[SUP]3[/SUP], Nijstad AL[SUP]1[/SUP], van Maarseveen EM[SUP]1[/SUP], Sikma MA[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous hemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.
PMID: 29185991 DOI: 10.3851/IMP3210